期刊文献+

西格列汀联合地特胰岛素治疗老年2型糖尿病的疗效研究 被引量:1

Efficacy of Sitagliptin Combined with Detemir in the Treatment of Type 2 Diabetes in the Elderly
下载PDF
导出
摘要 目的格列汀联合地特胰岛素治疗老年2型糖尿病的疗效研究。方法择在该院进行2型糖尿病治疗的68例老年患者进行调查,选取时间为2018年2月-2019年1月。将患者分为两组,每组34例。对比组采用常规治疗方式,实验组采用了西格列汀联合地特胰岛素治疗方式。分析两组最终的治疗结果。结果对比组患者胰岛素使用剂量和实验组相比较高,差异有统计学意义(P<0.05);对比组HbAlc水平、2 hPG水平、FBG水平和实验组相比较高,差异有统计学意义(P<0.05)。结论老年2型糖尿病治疗中,可采取西格列汀联合地特胰岛素治疗方式,效果优异。 Objective The efficacy of glitatine combined with insulin detemir in the treatment of type 2 diabetes in the elderly. Methods A total of 68 elderly patients undergoing type 2 diabetes treatment in the hospital were selected for investigation, and the selection time was 2018.2-2019.1. Patients were divided into 2 groups of 34 patients each. The comparison group was treated with conventional treatment, and the experimental group was treated with sitagliptin combined with insulin detemir. The final treatment results of the two groups were analyzed. Results Compared with the experimental group, the dosage of insulin in the patients in the comparison group was higher than that in the experimental group, with a statistically significant difference(P<0.05);the HbAlc level, 2 hPG level, and FBG level in the comparison group were higher than those in the experimental group, with statistically significant differences(P<0.05). Conclusion In the treatment of elderly patients with type 2 diabetes, sitagliptin combined with insulin detemir can be used. The effect is excellent and it is worthy of application.
作者 孙绍娜 徐国豪 SUN Shao-na;XU Guo-hao(Department of Endocrinology,Laixi People's Hospital,Qingdao,,Shandong Province,266600 China;Department of Cardiology,Laixi People's Hospital,Qingdao,Shandong Province,266600 China)
出处 《糖尿病新世界》 2020年第7期68-69,共2页 Diabetes New World Magazine
关键词 糖尿病 胰岛素 西格列汀 Diabetes Insulin Sitagliptin
  • 相关文献

参考文献8

二级参考文献53

  • 1Awadhesh K Arya,Richik Tripathi,Santosh Kumar,Kamlakar Tripathi.Recent advances on the association of apoptosis in chronic non healing diabetic wound[J].World Journal of Diabetes,2014,5(6):756-762. 被引量:15
  • 2傅勇,李蓬秋.GLP-1抗糖尿病作用研究进展[J].实用糖尿病杂志,2007,3(3):53-55. 被引量:8
  • 3石巧荣,田进文,王丽英.2型糖尿病与炎症及抗炎治疗进展[J].实用医学杂志,2007,23(15):2289-2291. 被引量:12
  • 4Gu N,Kim BH,Rhim H,et al.Comparison of the bioavailability andtolerability of fixed-dose combination glimepiride/metformin/500mgtablets versus separate tablets:A single-dose,randomize dsequence,open-label,two-period crossover study in healthy Koreanvolunteers[J].Clin Ther,2010,32(7):1408-1418.
  • 5Soran H,Younis N.Insulin detemir:A new basal insulin analogue[J].Diabetes Obes Metab,2006,8(1):26-30.
  • 6Bohannon N.Overview of the gliptin class(dipeptidylpeptidase 24 in-hibitors) in clinical practice[J].Postgrad Med,2009,121(1):40.
  • 7Mohan V,Yang W,Son HY,et al.Efficacy and safety of sitagliptin inthe treatment of patients with type 2 diabetes in China?India,and ko-rea[J].Diabetes Res Clin Pract,2009,83(1):106-116.
  • 8Domhorst A,Luddeke HJ,Koenen C Transferring to insulin detemirfrom NPH insulin or insulin glargine in type 2 diabetes patients onbasal-only therapy with oral antidiabetic drugs improves glycaemiccontrol and reduces weight gain and risk of hypoglycaemia 14-weekfollow-up data from PREDICTIVE [J].Diabetes Obes Metab,2008?10(1):75-81.
  • 9International Diabetes Federation. Brussels, Belgium: IDF. Last updated 2012. IDF Diabetes Atlas Update. 2012. http'J/www.idf.org/diabetesatlas.
  • 10Whiting DR, Guariguata L, Weil C, et al. IDF Diabetes Atlas: global estimates of the prevalence of diabetes for 2011 and 2030[J]. Diabetes Res Clin Pract,2011,94:311-321.

共引文献79

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部